Jeff Held

Senior Vice President, General Counsel at Deciphera Pharmaceuticals LLC

Jeff Held

Jeff Held

Senior Vice President, General Counsel at Deciphera Pharmaceuticals LLC

Overview
Career Highlights

Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals LLC
Proteostasis Therapeutics, Inc.

RelSci Relationships

752

Birthday

1969

Age

52

Contact Data
Trying to get in touch with Jeff Held? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Jeff Held likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Founder at Deciphera Pharmaceuticals, Inc.

Relationship likelihood: Strong

Adjuncat Clinical Professor at University of Michigan - Flint

Relationship likelihood: Strong

Executive Vice President, Chief Financial Officer & Treasurer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Senior Vice President, Chief Technical Officer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Senior Advisor, Life Sciences Team at Frazier Healthcare Partners

Relationship likelihood: Strong

Chief Commercial Officer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Executive Vice President, Chief Medical Officer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Chief Business Officer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Senior Vice President, Head of International at Deciphera Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Jeff Held
Potential Connections via
Relationship Science
You
Jeff Held
Senior Vice President, General Counsel at Deciphera Pharmaceuticals LLC
Career History
Vice President, General Counsel & Secretary
2010 - 2011

HeartWare is a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life. The company’s innovative technologies are creating advances in the miniaturization of Ventricular Assist Devices (VADs) leading to less invasive surgical procedures and increasing the patient population who may be suitable for VAD therapy. Heart failure is a degenerative, terminal disease affecting more than 20 million patients worldwide and causing more than 7.25 million deaths each year. Approximately 1 million patients suffer from Class IV heart failure, the most severe stage of the disease. Heart transplantation is a proven treatment option for class IV heart failure patients, but a limited number of donor hearts become available each year. Ventricular assist devices can provide circulatory support until a donor heart becomes available (called bridge-to-transplant therapy), or provide long-term support as an alternative to transplantation (called destination therapy in many countries). HeartWare’s breakthrough innovations begin with the company’s miniaturized ventricular assist device, called the HVAD® Pump, designed to be implanted next to the heart in the pericardial space avoiding the more invasive surgical procedures required with older LVAD technologies. HeartWare® Ventricular Assist System Featuring the HVAD Pump is Available Around the World The HeartWare Ventricular Assist System obtained U.S. market approval in November 2012 from the U.S. Food and Drug Administration (FDA) as a bridge-to-transplant therapy for patients with advanced stage heart failure. The HeartWare® System has been commercially available in other global markets including Europe and Australia, since 2009. To date, more than 2,500 patients worldwide have been treated with the HeartWare® Ventricular Assist System. HeartWare is listed on the NASDAQ Stock Market under the symbol HTWR, and the Australian Securities Exchange under the symbol HIN. HeartWare’s corporate headquarters are in Framingham, Massachusetts. The company’s operating and manufacturing activities are based in Miami Lakes, Florida, and Sydney, NSW, Australia.

Vice President, Deputy General Counsel & Assistant Secretary
2006 - 2010

3com Megahertz Corp. provides voice and data networking products and services. The company was founded by Robert M. Metcalfe, Howard S. Charney and John P. Marshall in 1979 and is headquartered in Marlborough, MA.

Secretary & General Counsel
2016 - Prior

Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.

Transactions
Details Hidden

HeartWare International, Inc. issued USD Common Stock

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jeff Held. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jeff Held's profile does not indicate a business or promotional relationship of any kind between RelSci and Jeff Held.